688363 Bloomage Biotechnology Corporation Limited
- 59.92
- +1.15+1.96%
Bloomage Biotechnology Corporation Limited News
Why Investors Shouldn't Be Surprised By Bloomage BioTechnology Corporation Limited's (SHSE:688363) P/E
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 29x, you may consider Bloomage BioTechnology Corporation Limited (SHSE:688363) as a stock to avoid entirely w
Huaxi Biotech's “influencer” transformation or what is a custom synthetic creature in the shell
“Investor Network” Cai Jun is standing in the midst of ups and downs, and Huaxi Biotech (688363.SH, hereinafter referred to as the “Company”) is probably still in the rain. In April of this year, the company announced the departure of Ma Shouwei, the former core technician. According to data, Ma Shouwei was previously the functional skincare development director at the Shanghai R&D Center, where he was mainly responsible for basic formulation technology and functional product formulation research and development. Prior to joining the company, he had experience with international brands such as Unilever and L'Oréal. Ma Shouwei's research and development field is mainly cosmetics. This is in line with the company's efforts over the past few years, which is to transform from hyaluronic acid raw materials to a cosmetics company. However, the company said goodbye in 2023
Huaxi Biotech (688363.SH): spent 204 million yuan to repurchase a total of 3.0402 million shares
Gelonghui, April 1, 丨 Huaxi Biotech (688363.SH) announced that as of March 31, 2024, the company had repurchased a total of 3,0402 million shares through the Shanghai Stock Exchange trading system, accounting for 0.6312% of the company's total share capital. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 204 million (excluding transaction fees such as stamp duty and transaction fees).
Express News | Huaxi Biotech invests in the establishment of a management consulting company with businesses related to artificial intelligence
Express News | Huaxi Biotech Beijing invests in the establishment of a new company including health food sales business
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Last Week's 3.6% Decline Must Have Disappointed Private Equity Firms Who Have a Significant Stake
Key Insights Bloomage BioTechnology's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public The largest shareholder of the
Huaxi Biotech (688363.SH): A total of 2.71 million shares were repurchased at a cost of 183 million yuan
Gelonghui, March 5, 丨 Huaxi Biotech (688363.SH) announced that as of February 29, 2024, the company had repurchased 2.71 million shares of the company's shares through centralized bidding transactions, accounting for 0.5626% of the company's total share capital of 481,678,242 shares. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 183 million (excluding transaction fees such as stamp duty and transaction fees).
*ST Beauty Valley (000615.SZ): Some medical and aesthetic consumables are Huaxi Biotech products
Gelonghui March 5 | An investor asked *ST Meigu (000615.SZ) on the investor interactive platform, “How are your company's cooperation discussions with Huaxi Biotech?” The company replied that some of the company's medical and aesthetic consumables are Huaxi Biotech products.
Huaxi Biotech (688363): Management changes have dragged down 23 years of performance, waiting for an inflection point in business
Looking back on the incident, the company announced its 2023 performance report. In 2023, the company achieved operating income of 6.081 billion yuan, a decrease of 4.4%; realized net profit attributable to mother of 587 million yuan, a decrease of 39.5%; and realized net profit deducted from non-mother
Bloomage Biotech Names CFO
Bloomage Biotechnology (SHA:688363) appointed Wang Hui as chief financial officer, according to a Thursday filing. Wang will take over from Luan Yizheng, who was named as the Chinese biomedical produc
Huaxi Biotech (688363) Comment: Revenue is expected to drop by about 4% in '23, and management changes are being upgraded and implemented throughout the year
The company released its 23-year performance forecast, which was slightly lower than market expectations. 1) The estimated revenue for '23 was 6.08 billion yuan, down 4.4% year on year. Net profit to mother is estimated to be 587 million yuan, down 39.5% year on year, after deducting non-net profit
Huaxi Biotech (688363.SH) appoints Wang Hui as the company's financial director
Huaxi Biotech (688363.SH) announced that on February 28, 2024, the board of directors of the company reviewed and approved “On...
Express News | Huaxi Biotech Performance Report: Net profit of 2023 was 587 million yuan, a year-on-year decrease of 39.5%.
Huaxi Biotech (688363.SH): As of February 20, 2024, the number of shareholders of the company was 35,759
Gelonghui, Feb. 23 | Huaxi Biotech (688363.SH) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 35,759.
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Bloomage BioTechnology (SHSE:688363) has had a rough three months with its share price down 21%. However, a closer look at its sound financials might cause you to think again. Given that fundamental
Huaxi Biotech (688363.SH) has repurchased a total of 2,336,800 shares at a cost of 160 million yuan
Huaxi Biotech (688363.SH) announced that as of January 31, 2024, the company passed the Shanghai Stock Exchange...
Bloomage BioTechnology (SHSE:688363) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Huaxi Biotech (688363.SH): As of January 19, 2024, the number of shareholders of the company was 37,924
Gelonghui, January 25丨Huaxi Biotech (688363.SH) said on the investor interactive platform that as of January 19, 2024, the number of shareholders of the company was 37,924.
Huaxi Biotech (688363.SH): As of January 10, 2024, the number of shareholders of the company was 38011
Gelonghui, January 15, 丨 Huaxi Biotech (688363.SH) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 38,011.
Is Bloomage BioTechnology Corporation Limited (SHSE:688363) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bloomage BioTechnology fair value estimate is CN¥47.48 Bloomage BioTechnology is estimated to be 33% overvalued based on current share price
Analysis
Price Target
No Data
